Learning Objectives:

  • Overview of the diagnosis and assessment of immune checkpoint inhibitor (ICI) therapy related adverse events.
  • Review current data on risk of immune mediated diarrhea and colitis (IMDC) in patients with cancer and pre-existing IBD after initiating ICI therapy.
  • Review optimal workup and management considerations in patients with pre-existing IBD.
Session date: 
06/06/2023 - 4:30pm to 5:30pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Tenzin Choden